WO2014203140A1 - Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof - Google Patents

Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof Download PDF

Info

Publication number
WO2014203140A1
WO2014203140A1 PCT/IB2014/062251 IB2014062251W WO2014203140A1 WO 2014203140 A1 WO2014203140 A1 WO 2014203140A1 IB 2014062251 W IB2014062251 W IB 2014062251W WO 2014203140 A1 WO2014203140 A1 WO 2014203140A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetaminophen
solid oral
oral pharmaceutical
pharmaceutical composition
composition
Prior art date
Application number
PCT/IB2014/062251
Other languages
French (fr)
Inventor
Yatendra Kumar
Kapileshwar SWAIN
Vijay SUGGALA
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority claimed from IN2110MU2013 external-priority patent/IN2013MU02110A/en
Priority claimed from IN2111MU2013 external-priority patent/IN2013MU02111A/en
Publication of WO2014203140A1 publication Critical patent/WO2014203140A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Definitions

  • the present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof.
  • the present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof, one or more alkalizers, and other pharmaceutically acceptable excipients.
  • the compositions of the present invention exhibit improved/faster dissolution profile of one or more active ingredients.
  • the invention further relates to process of preparing said pharmaceutical compositions and their use as antispasmodic.
  • Muscle spasm is an involuntary contraction of a muscle. Muscle spasms occur suddenly, usually resolve quickly, and are often painful. Muscle spasm is most commonly refers to a muscle cramp which is often accompanied by a sudden burst of pain, but is usually harmless and ceases after a few minutes. There are a variety of other causes of involuntary muscle contractions, which may be more serious, depending on the cause.
  • Antispasmodics are the agents used for smooth muscle contraction, especially in tubular organs of the gastrointestinal tract. Smooth muscles line most of the visceral organs. The peristalsis and muscular activity of the stomach, intestines, gall bladder, urinary bladder, lung, the uterus, and to a degree the heart are all largely controlled by smooth muscles. Smooth muscles are innervated by the autonomic nervous system. The effect is to prevent spasms of the stomach, intestine or urinary bladder. Dicyclomine is used as an antispasmodic due to its anti-cholinergic action.
  • Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent, indicated for management of mild to moderate pain with or without adjunctive opioid analgesics. Its chemical name is N-acetyl-p-aminophenol. Acetaminophen has a molecular weight of 151 .16 with the following structural formula:
  • Dicyclomine is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. It relieves muscle spasms and cramping in the gastrointestinal tract by blocking the activity of acetylcholine on cholinergic (or muscarinic) receptors on the surface of muscle cells. It is a smooth muscle relaxant.
  • Dicyclomine is [bicyclohexyl]-1 carboxylic acid, 2-(diethylamino) ethyl ester, with a molecular fo following structural formula:
  • Hydrochloride salt of dicyclomine is currently marketed under brand name Bentyl® in US for treatment of functional bowel/irritable bowel syndrome.
  • Dextropropoxyphene is (1 S,2R)-1 -benzyl-3-(dimethylamino)-2-methyl-1 - phenylpropyl propionate an analgesic in the opioid category, with a molecular formula C22H20NO2 and the following structural formula:
  • Dextropropoxyphene is currently marketed under brand name Parvodex ® in India as an analgesic (opioid).
  • U.S. Patent No. 8,268,352 discloses modified release composition for highly soluble drugs comprising acetaminophen & dicyclomine.
  • U.S. Patent No. 8,263,125 discloses immediate release and modified release composition for highly soluble drugs comprising acetaminophen & dicyclomine.
  • U.S. Patent No. 7,776,844 discloses pharmaceutical formulation comprising acetaminophen & dicyclomine.
  • U.S. Patent No. 7,038,085 discloses pharmaceutical composition comprising acetaminophen & dextropropoxyphene.
  • U.S. Patent No. 6,730,321 & U.S. Patent No. 6,372,254 discloses press coated tablet, pulsatile drug delivery system comprising acetaminophen & dextropropoxyphene.
  • U.S. Patent No. 6,160,020 discloses pharmaceutical composition comprising acetaminophen & dicyclomine.
  • U.S. Patent No. 5,053,396 discloses pharmaceutical composition comprising acetaminophen & dextropropoxyphene hydrochloride.
  • U.S. Patent No. 4,952,402 discloses controlled release powder comprising acetaminophen & dicyclomine and process for its preparation.
  • Muscle spasms occur suddenly, and are often painful. Muscle spasm is accompanied by a sudden burst of pain.
  • Antispasmodics, analgesics are the agents useful in these conditions, in presently available formulations not a single agent or combinations of these agents gives faster release. Hence it is necessary to develop the composition, which will give immediate as well as faster release of the agents useful in these conditions.
  • the inventors of the present invention have surprisingly found that by using alkalizer in the fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof, or particularly by using the alkalizer in optimized amount, it is possible to achieve desirable or improved drug release.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine hydrochloride & dextropropoxyphene napsylate, wherein the composition comprises one or more alkalizers.
  • an immediate release solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and pharmaceutically acceptable excipients.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and one or more pharmaceutically acceptable excipient comprising fillers, glidants, alkalizers, lubricants, anti-adherents, disintegrants, flavours, colours, preservatives, sweetners, and binders.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein acetaminophen or its salt is present in the form of at least two different portions of the particles each having different particle size.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers and acetaminophen or its salt is present in the form mixture of particles having size less than about 300 microns and particles having size in the range of about 300 microns to about 1200 microns.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, and one or more alkalizers selected from alkali earth metal salts; alkali metal carbonates or bicarbonates such as lithium, sodium, or potassium carbonate, or lithium, sodium, or potassium bicarbonate; tertiary amines, such as triethylamine, tributylamine, N-methylmorpholine; salts of phosphoric acid such as sodium, potassium, calcium, magnesium and aluminium; citric acid or other suitable weak inorganic or organic acids, aluminium, calcium and magnesium hydroxides; magnesium oxide, trihydroxymethylaminomethane or mixtures thereof.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, sodium bicarbonate, and one or more pharmaceutically acceptable excipients.
  • composition of the present invention is in the form of powder, tablets, pellets, capsules, granules or pellets filled in capsule, tablet in capsule, multilayer tablet, a bilayer tablet, a trilayer tablet, or premixed powder filled in capsule.
  • a method of improving the in-vitro dissolution profile (% drug release) of acetaminophen, dicyclomine or dextropropoxyphene or salts thereof comprises using one or more alkalizers in the composition.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and the amount of acetaminophen ranges from about 10% w/w to about 95% w/w, the amount of dicyclomine ranges from about 0.01 % w/w to about 50% w/w and the amount of dextropropoxyphene ranges from about 0.5% w/w to about 70% w/w of the composition.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the amount of alkalizer in the composition ranges from about 0.1 % w/w to about 50% w/w of the composition.
  • a process of preparing the solid oral pharmaceutical composition of acetaminophen, dicyclomine & dextropropoxyphene or salts thereof comprises steps of: (a) sifting acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, one or more alkalizers and one or more pharmaceutically acceptable excipients; and
  • step (b) formulating the mixture prepared in step (a) in a solid oral dosage form.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers, characterized in that said composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 90% of the total acetaminophen is released until 20 minutes; and more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 1 dissolution test method at 100 rpm using 900ml of pH 4.5 acetate buffer for 60 minutes.
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers characterized in that said composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 85% of the total acetaminophen is released until 20 minutes; more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 2 (paddle with sinker) dissolution test method at 30 rpm using 900ml of 0.05M HCI for 60 minutes.
  • a method of treating muscle spasms, spasmodic pains, renal, ureteric, biliary or intestinal colic, spasmodic dysmenorrhoea in a patient in need thereof comprises of administering the pharmaceutical composition as described herein.
  • the present invention provides a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, and one or more alkalizers.
  • the compositions of the invention are useful as antispasmodics in the treatment of muscle spasms, which requires immediate drug release and subsequently, its therapeutic action.
  • alkalizer used herein throughout the specification means an agent that counteracts or neutralizes acidity or creates alkaline pH around active ingredients.
  • immediate release refers that within 2 hours, preferably within 1 .5 hour, more preferably within 1 hour and most preferably within 20 minutes, at least 80%, preferably at least 85%, more preferably at least 90% of the drug being present in the compartment is dissolved or released.
  • acetaminophen refers to acetaminophen base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
  • dicyclomine refers to dicyclomine base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
  • dextropropoxyphene refers to dextropropoxyphene base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
  • the solid oral pharmaceutical composition comprises acetaminophen, dicyclomine hydrochloride & dextropropoxyphene napsylate, and one or more alkalizers.
  • the dextropropoxyphene used in the composition is dextropropoxyphene hydrochloride or dextropropoxyphene napsylate.
  • Preferred salt is dextropropoxyphene napsylate.
  • the inventors of the present invention have also surprisingly found that when at least two different types of particles of the active agents, differing in particle size, are used in the composition, the composition substantiates desired and improved release.
  • the solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises an alkalizer and characterized in that acetaminophen or its salt is present in the form mixture of particles having size less than about 300 microns and particles having size in the range of about 300 microns to about 1200 microns.
  • the amount of acetaminophen in the composition may range from about 10% w/w to about 95% w/w of the composition.
  • the amount of acetaminophen in the composition ranges from about 40% w/w to about 80% w/w of the composition.
  • the amount of dicyclomine in the composition may range from about 0.01 % w/w to about 50% w/w of the composition. Preferably, the amount of dicyclomine in the composition ranges from about 0.1 % w/w to about 20% w/w of the composition.
  • the amount of dextropropoxyphene in the composition may range from about 0.5% w/w to about 70% w/w of the composition. Preferably, the amount of dextropropoxyphene in the composition ranges from about 2% w/w to about 40% w/w of the composition.
  • Suitable alkalizers for use in the present invention include, but not limited to alkali earth metal salts; alkali metal carbonates or bicarbonates, tertiary amines, buffering agents or mixtures thereof.
  • alkalizers includes, but not limited to sodium carbonate, sodium bicarbonate, lithium carbonate, lithium bicarbonate, potassium carbonate, potassium bicarbonate, triethylamine, tributylamine, N-methylmorpholine, sodium phosphate, potassium phosphate, calcium phosphate, magnesium phosphate, aluminium phosphate, citric acid, potassium citrate, aluminium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, trihydroxymethylaminomethane or mixtures thereof.
  • alkali metal carbonates or bicarbonates are used. More preferably, sodium bicarbonate is used.
  • the amount of alkalizers in the composition may range from about 0.1 % w/w to about 50% w/w of the composition. Preferably, the amount of alkalizers in the composition ranges from about 1 % w/w to about 30% w/w of the composition. More preferably, the amount of alkalizers in the composition ranges from about 1 % w/w to about 20% w/w of the composition.
  • the solid oral pharmaceutical composition of the invention further may comprise one or more pharmaceutical excipients suitable for oral administration.
  • excipients may be selected from one or more binders, fillers, filler-binders, disintegrants, glidants, alkalizers, antiadherents, sweeteners, flavouring and colouring agents.
  • the composition comprises one or more alkalizers, glidants/lubricants and fillers.
  • Lubricants/glidants suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from one or more of stearic acid, talc, siliconised talc, sodium stearyl fumarate and magnesium stearate.
  • Preferable lubricant/glidants is magnesium stearate.
  • Fillers or filler-binder suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogen phosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, xylitol, or mixtures thereof.
  • Preferable fillers and/or filler-binders are selected from pregelatinized starch, microcrystalline cellulose, lactose monohydrate, lactose, or mixtures thereof.
  • Binders suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from one or more of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch.
  • ovidone polyvinyl pyrrolidone
  • Copovidone copolymers of vinylpyrrolidone with other vinylderivatives
  • hydroxypropyl methylcellulose methylcellulose
  • hydroxypropylcellulose powdered acacia
  • gelatin guar gum
  • carbomer such as carbopol, polymethacrylates and starch.
  • the solid oral pharmaceutical composition comprises-
  • the invention further provides a process of preparing the solid oral pharmaceutical composition of acetaminophen, dicyclomine & dextropropoxyphene or salts thereof.
  • the process comprises steps of: (a) sifting acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, one or more alkalizers and one or more pharmaceutically acceptable excipients; and
  • step (b) formulating the mixture prepared in step (a) in a solid oral dosage form.
  • active ingredients and alkalizers are sifted either separately or together.
  • active ingredients are sifted together.
  • the process of preparing the solid oral pharmaceutical composition comprises steps of:
  • step (c) sifting mixture of step (b) with second part quantity of acetaminophen or salts thereof;
  • step (d) blending mixture of step (c) with remaining quantity of dextropropoxyphene or salts thereof;
  • step (e) blending mixture of step (d) with final quantity of acetaminophen or salts thereof;
  • step (f) blending mixture of step (e) with premixed and pre-sifted mixture of filler and alkalizer.
  • step (g) blending mixture of step (f) with lubricant
  • step (h) formulating the lubricated blend of step (g) in to a solid oral dosage form.
  • the solid oral pharmaceutical composition of the present invention may be formulated is in the form of powder, tablets, pellets, capsules, granules or pellets filled in capsule, tablet in capsule, multilayer tablet, a bilayer tablet, a trilayer tablet, or premixed powder filled in capsule.
  • the invention further provides a method of treating muscle spasms, spasmodic pains, renal, ureteric, biliary or intestinal colic, spasmodic dysmenorrhoea in a human in need thereof, wherein method comprises of administering the solid oral pharmaceutical composition as described herein
  • Example 1 Acetaminophen, Dicyclomine HCI and Dextropropoxyphene Napsylate Capsules
  • Formulation of fixed dose combination of Acetaminophen, Dicyclomine HCI and Dextropropoxyphene Napsylate was prepared with and without sodium bicarbonate and was characterized for in-vitro % drug release of acetaminophen in Medium I & Medium II.
  • Acetaminophen (crystalline) was sifted through 20 mesh.
  • the retentions on 20 mesh was milled through multimill (Impact forward and slow speed) and by using 2.0 mm screen.
  • the milled material was sifted through 20 mesh.
  • the milling process was repeated by using 1 .0 mm screen through multimill (Impact forward and fast speed) if retentions observed.
  • Dicyclomine Hydrochloride was co-sifted with half quantity of Dextropropoxyphene napsylate through 20 mesh to form Premix I.
  • the premix I was co-sifted with Acetaminophen (fine) through 20 mesh to form Premix II.
  • the premix II was loaded into blender and mixed for 20 minutes.
  • remaining quantity of Dextropropoxyphene napsylate was loaded into blender and mixed for 10 minutes to form Premix III.
  • Acetaminophen (crystalline) was loaded with Premix III in a blender and mixed for 20 minutes to form Premix IV.
  • Example 2 Dissolution study of Example 1 (USP Apparatus 1)
  • Example 3 Dissolution study of Example 1 (USP Apparatus 2)
  • Dissolution study of formulation I and II of example 1 was carried out according to method USP Apparatus 2 (paddle with sinkers), by using 900ml of 0.05M HCI for 60 minutes at 30 rpm.

Abstract

The present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof, one or more alkalizers, and other pharmaceutically acceptable excipients. The compositions of the present invention exhibit improved/faster dissolution profile of one or more active ingredients. The invention further relates to process of preparing said pharmaceutical compositions and their use as antispasmodic.

Description

SOLID ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING FIXED
DOSE COMBINATION OF ACETAMINOPHEN. DICYCLOMINE AND
DEXTROPROPOXYPHENE OR SALTS THEREOF
Field of the Invention
The present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof, one or more alkalizers, and other pharmaceutically acceptable excipients. The compositions of the present invention exhibit improved/faster dissolution profile of one or more active ingredients. The invention further relates to process of preparing said pharmaceutical compositions and their use as antispasmodic.
Background of the Invention
Muscle spasm is an involuntary contraction of a muscle. Muscle spasms occur suddenly, usually resolve quickly, and are often painful. Muscle spasm is most commonly refers to a muscle cramp which is often accompanied by a sudden burst of pain, but is usually harmless and ceases after a few minutes. There are a variety of other causes of involuntary muscle contractions, which may be more serious, depending on the cause.
Antispasmodics are the agents used for smooth muscle contraction, especially in tubular organs of the gastrointestinal tract. Smooth muscles line most of the visceral organs. The peristalsis and muscular activity of the stomach, intestines, gall bladder, urinary bladder, lung, the uterus, and to a degree the heart are all largely controlled by smooth muscles. Smooth muscles are innervated by the autonomic nervous system. The effect is to prevent spasms of the stomach, intestine or urinary bladder. Dicyclomine is used as an antispasmodic due to its anti-cholinergic action.
Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent, indicated for management of mild to moderate pain with or without adjunctive opioid analgesics. Its chemical name is N-acetyl-p-aminophenol. Acetaminophen has a molecular weight of 151 .16 with the following structural formula:
Figure imgf000003_0001
Dicyclomine is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. It relieves muscle spasms and cramping in the gastrointestinal tract by blocking the activity of acetylcholine on cholinergic (or muscarinic) receptors on the surface of muscle cells. It is a smooth muscle relaxant. Dicyclomine is [bicyclohexyl]-1 carboxylic acid, 2-(diethylamino) ethyl ester, with a molecular fo following structural formula:
Figure imgf000003_0002
Hydrochloride salt of dicyclomine is currently marketed under brand name Bentyl® in US for treatment of functional bowel/irritable bowel syndrome.
Dextropropoxyphene is (1 S,2R)-1 -benzyl-3-(dimethylamino)-2-methyl-1 - phenylpropyl propionate an analgesic in the opioid category, with a molecular formula C22H20NO2 and the following structural formula:
Figure imgf000004_0001
Dextropropoxyphene is currently marketed under brand name Parvodex® in India as an analgesic (opioid).
These three active agents namely acetaminophen, dicyclomine and dextropropoxyphene are also available in fixed dose combination dosage form. For instance, in India the fixed dose combination product is available for treatment of spasmodic pains under trade name Spasmo-Proxyvon®.
U.S. Patent No. 8,268,352 discloses modified release composition for highly soluble drugs comprising acetaminophen & dicyclomine.
U.S. Patent No. 8,263,125 discloses immediate release and modified release composition for highly soluble drugs comprising acetaminophen & dicyclomine.
U.S. Patent No. 7,776,844 discloses pharmaceutical formulation comprising acetaminophen & dicyclomine.
U.S. Patent No. 7,038,085 discloses pharmaceutical composition comprising acetaminophen & dextropropoxyphene.
U.S. Patent No. 6,730,321 & U.S. Patent No. 6,372,254 discloses press coated tablet, pulsatile drug delivery system comprising acetaminophen & dextropropoxyphene. U.S. Patent No. 6,160,020 discloses pharmaceutical composition comprising acetaminophen & dicyclomine.
U.S. Patent No. 5,053,396 discloses pharmaceutical composition comprising acetaminophen & dextropropoxyphene hydrochloride.
U.S. Patent No. 4,952,402 discloses controlled release powder comprising acetaminophen & dicyclomine and process for its preparation.
Muscle spasms occur suddenly, and are often painful. Muscle spasm is accompanied by a sudden burst of pain. Antispasmodics, analgesics are the agents useful in these conditions, in presently available formulations not a single agent or combinations of these agents gives faster release. Hence it is necessary to develop the composition, which will give immediate as well as faster release of the agents useful in these conditions.
Within the pharmaceutical art, the formulation of multiple pharmaceutically active compounds into usable dosage forms, in which the release of one or more active ingredients is faster, may be challenging and, frequently, unpredictable. Although various methods have been suggested in the art to improve the drug release from the fixed dose combination formulations, it is highly uncertain to devise an ideal formulation of a particular drug combination by legitimate selection of excipients.
The inventors of the present invention have found that although several formulations have been suggested in the arts for combination of acetaminophen with either dicyclomine or dextropropoxyphene, or their fixed dose combination, these formulations still may not exhibit the desired release profile of the active ingredients. Hence, there still exists an enduring need for an alternate, improved fixed dose combination formulation of acetaminophen, dicyclomine and dextropropoxyphene with an improved release of one or more of these active pharmaceutical agents.
The inventors of the present invention have surprisingly found that by using alkalizer in the fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof, or particularly by using the alkalizer in optimized amount, it is possible to achieve desirable or improved drug release.
Summary of the Invention
In one general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine hydrochloride & dextropropoxyphene napsylate, wherein the composition comprises one or more alkalizers.
In another general aspect, there is provided an immediate release solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and pharmaceutically acceptable excipients. In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and one or more pharmaceutically acceptable excipient comprising fillers, glidants, alkalizers, lubricants, anti-adherents, disintegrants, flavours, colours, preservatives, sweetners, and binders.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein acetaminophen or its salt is present in the form of at least two different portions of the particles each having different particle size.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers and acetaminophen or its salt is present in the form mixture of particles having size less than about 300 microns and particles having size in the range of about 300 microns to about 1200 microns.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, and one or more alkalizers selected from alkali earth metal salts; alkali metal carbonates or bicarbonates such as lithium, sodium, or potassium carbonate, or lithium, sodium, or potassium bicarbonate; tertiary amines, such as triethylamine, tributylamine, N-methylmorpholine; salts of phosphoric acid such as sodium, potassium, calcium, magnesium and aluminium; citric acid or other suitable weak inorganic or organic acids, aluminium, calcium and magnesium hydroxides; magnesium oxide, trihydroxymethylaminomethane or mixtures thereof. In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, sodium bicarbonate, and one or more pharmaceutically acceptable excipients.
In another general aspect, the composition of the present invention is in the form of powder, tablets, pellets, capsules, granules or pellets filled in capsule, tablet in capsule, multilayer tablet, a bilayer tablet, a trilayer tablet, or premixed powder filled in capsule.
In another general aspect, there is provided a method of improving the in-vitro dissolution profile (% drug release) of acetaminophen, dicyclomine or dextropropoxyphene or salts thereof, which method comprises using one or more alkalizers in the composition.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition comprises one or more alkalizers and the amount of acetaminophen ranges from about 10% w/w to about 95% w/w, the amount of dicyclomine ranges from about 0.01 % w/w to about 50% w/w and the amount of dextropropoxyphene ranges from about 0.5% w/w to about 70% w/w of the composition.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the amount of alkalizer in the composition ranges from about 0.1 % w/w to about 50% w/w of the composition.
In another general aspect, there is provides a process of preparing the solid oral pharmaceutical composition of acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, which process comprises steps of: (a) sifting acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, one or more alkalizers and one or more pharmaceutically acceptable excipients; and
(b) formulating the mixture prepared in step (a) in a solid oral dosage form.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers, characterized in that said composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 90% of the total acetaminophen is released until 20 minutes; and more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 1 dissolution test method at 100 rpm using 900ml of pH 4.5 acetate buffer for 60 minutes.
In another general aspect, there is provided a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises one or more alkalizers characterized in that said composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 85% of the total acetaminophen is released until 20 minutes; more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 2 (paddle with sinker) dissolution test method at 30 rpm using 900ml of 0.05M HCI for 60 minutes.
In another general aspect, there is provided a method of treating muscle spasms, spasmodic pains, renal, ureteric, biliary or intestinal colic, spasmodic dysmenorrhoea in a patient in need thereof, wherein method comprises of administering the pharmaceutical composition as described herein. Detailed Description of the Invention
The present invention provides a solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, and one or more alkalizers. The compositions of the invention are useful as antispasmodics in the treatment of muscle spasms, which requires immediate drug release and subsequently, its therapeutic action.
The term "alkalizer" used herein throughout the specification means an agent that counteracts or neutralizes acidity or creates alkaline pH around active ingredients.
The term "immediate release" used throughout the specification refers that within 2 hours, preferably within 1 .5 hour, more preferably within 1 hour and most preferably within 20 minutes, at least 80%, preferably at least 85%, more preferably at least 90% of the drug being present in the compartment is dissolved or released.
The term "acetaminophen" as used herein refers to acetaminophen base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
The term "dicyclomine" as used herein refers to dicyclomine base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
The term "dextropropoxyphene" as used herein refers to dextropropoxyphene base or its salts, solvates, prodrugs, hydrates, enantiomers or polymorphs thereof.
In an embodiment, the solid oral pharmaceutical composition comprises acetaminophen, dicyclomine hydrochloride & dextropropoxyphene napsylate, and one or more alkalizers. In a further embodiment, the dextropropoxyphene used in the composition is dextropropoxyphene hydrochloride or dextropropoxyphene napsylate. Preferred salt is dextropropoxyphene napsylate.
The inventors of the present invention have also surprisingly found that when at least two different types of particles of the active agents, differing in particle size, are used in the composition, the composition substantiates desired and improved release.
In an embodiment, the solid oral pharmaceutical composition comprising acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, wherein the composition further comprises an alkalizer and characterized in that acetaminophen or its salt is present in the form mixture of particles having size less than about 300 microns and particles having size in the range of about 300 microns to about 1200 microns.
The amount of acetaminophen in the composition may range from about 10% w/w to about 95% w/w of the composition. Preferably, the amount of acetaminophen in the composition ranges from about 40% w/w to about 80% w/w of the composition.
The amount of dicyclomine in the composition may range from about 0.01 % w/w to about 50% w/w of the composition. Preferably, the amount of dicyclomine in the composition ranges from about 0.1 % w/w to about 20% w/w of the composition.
The amount of dextropropoxyphene in the composition may range from about 0.5% w/w to about 70% w/w of the composition. Preferably, the amount of dextropropoxyphene in the composition ranges from about 2% w/w to about 40% w/w of the composition. Suitable alkalizers for use in the present invention include, but not limited to alkali earth metal salts; alkali metal carbonates or bicarbonates, tertiary amines, buffering agents or mixtures thereof.
Suitable examples of alkalizers includes, but not limited to sodium carbonate, sodium bicarbonate, lithium carbonate, lithium bicarbonate, potassium carbonate, potassium bicarbonate, triethylamine, tributylamine, N-methylmorpholine, sodium phosphate, potassium phosphate, calcium phosphate, magnesium phosphate, aluminium phosphate, citric acid, potassium citrate, aluminium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, trihydroxymethylaminomethane or mixtures thereof. Preferably, alkali metal carbonates or bicarbonates are used. More preferably, sodium bicarbonate is used.
The amount of alkalizers in the composition may range from about 0.1 % w/w to about 50% w/w of the composition. Preferably, the amount of alkalizers in the composition ranges from about 1 % w/w to about 30% w/w of the composition. More preferably, the amount of alkalizers in the composition ranges from about 1 % w/w to about 20% w/w of the composition.
The solid oral pharmaceutical composition of the invention further may comprise one or more pharmaceutical excipients suitable for oral administration. Such excipients may be selected from one or more binders, fillers, filler-binders, disintegrants, glidants, alkalizers, antiadherents, sweeteners, flavouring and colouring agents. In an embodiment, the composition comprises one or more alkalizers, glidants/lubricants and fillers.
Lubricants/glidants suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from one or more of stearic acid, talc, siliconised talc, sodium stearyl fumarate and magnesium stearate. Preferable lubricant/glidants is magnesium stearate.
Fillers or filler-binder suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogen phosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, xylitol, or mixtures thereof. Preferable fillers and/or filler-binders are selected from pregelatinized starch, microcrystalline cellulose, lactose monohydrate, lactose, or mixtures thereof.
Binders suitable for use in the solid oral pharmaceutical composition of the present invention may be selected from one or more of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch.
In an embodiment, the solid oral pharmaceutical composition comprises-
(a) about 40% w/w to about 80% w/w of acetaminophen or salts thereof;
(b) about 0.1 % w/w to about 20% w/w of dicyclomine or salts thereof;
(c) about 2% w/w to about 40% w/w of dextropropoxyphene or salts thereof;
(d) about 1 % w/w to about 20% w/w of alkalizer;
(e) about 1 % w/w to about 60% w/w of filler; and
(f) about 0.001 % w/w to about 10% w/w of lubricant.
The invention further provides a process of preparing the solid oral pharmaceutical composition of acetaminophen, dicyclomine & dextropropoxyphene or salts thereof. The process comprises steps of: (a) sifting acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, one or more alkalizers and one or more pharmaceutically acceptable excipients; and
(b) formulating the mixture prepared in step (a) in a solid oral dosage form.
In an embodiment, active ingredients and alkalizers are sifted either separately or together. Preferably, active ingredients are sifted together.
In a further embodiment, the process of preparing the solid oral pharmaceutical composition comprises steps of:
(a) sifting a part quantity of acetaminophen or salts thereof;
(b) sifting dicyclomine with part quantity of dextropropoxyphene or salts thereof
(c) sifting mixture of step (b) with second part quantity of acetaminophen or salts thereof;
(d) blending mixture of step (c) with remaining quantity of dextropropoxyphene or salts thereof;
(e) blending mixture of step (d) with final quantity of acetaminophen or salts thereof;
(f) blending mixture of step (e) with premixed and pre-sifted mixture of filler and alkalizer.
(g) blending mixture of step (f) with lubricant; and
(h) formulating the lubricated blend of step (g) in to a solid oral dosage form.
The solid oral pharmaceutical composition of the present invention may be formulated is in the form of powder, tablets, pellets, capsules, granules or pellets filled in capsule, tablet in capsule, multilayer tablet, a bilayer tablet, a trilayer tablet, or premixed powder filled in capsule.
The invention further provides a method of treating muscle spasms, spasmodic pains, renal, ureteric, biliary or intestinal colic, spasmodic dysmenorrhoea in a human in need thereof, wherein method comprises of administering the solid oral pharmaceutical composition as described herein
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1 : Acetaminophen, Dicyclomine HCI and Dextropropoxyphene Napsylate Capsules
Formulation of fixed dose combination of Acetaminophen, Dicyclomine HCI and Dextropropoxyphene Napsylate was prepared with and without sodium bicarbonate and was characterized for in-vitro % drug release of acetaminophen in Medium I & Medium II.
Table 1
Figure imgf000015_0001
Process:
Acetaminophen (crystalline) was sifted through 20 mesh. The retentions on 20 mesh was milled through multimill (Impact forward and slow speed) and by using 2.0 mm screen. The milled material was sifted through 20 mesh. The milling process was repeated by using 1 .0 mm screen through multimill (Impact forward and fast speed) if retentions observed.
Dicyclomine Hydrochloride was co-sifted with half quantity of Dextropropoxyphene napsylate through 20 mesh to form Premix I. The premix I was co-sifted with Acetaminophen (fine) through 20 mesh to form Premix II. The premix II was loaded into blender and mixed for 20 minutes. Then remaining quantity of Dextropropoxyphene napsylate (presifted through 20 mesh) was loaded into blender and mixed for 10 minutes to form Premix III.
Acetaminophen (crystalline) was loaded with Premix III in a blender and mixed for 20 minutes to form Premix IV. Premixed and presifted (20 mesh) Siliconised talcum and sodium bicarbonate was loaded into Premix IV in blender and mixed for 20 minutes. Finally magnesium stearate was loaded into the blender & lubricated for 10 minutes. The resulting blend was then filled in size Oel' empty hard gelatine capsule using capsule filling machine.
Example 2: Dissolution study of Example 1 (USP Apparatus 1)
Dissolution study of formulation I and II of example 1 was carried out according to method USP Apparatus 1 (basket), by using 900ml of pH 4.5 acetate buffer for 60 minutes at 100 rpm. Table 2
Figure imgf000017_0002
Figure imgf000017_0001
The dissolution profile indicates that use of alkalizer in formulation II has resulted in relatively faster/immediate release of acetaminophen than that exhibited by formulation I. Example 3: Dissolution study of Example 1 (USP Apparatus 2)
Dissolution study of formulation I and II of example 1 was carried out according to method USP Apparatus 2 (paddle with sinkers), by using 900ml of 0.05M HCI for 60 minutes at 30 rpm.
Table 3
Figure imgf000018_0002
Figure imgf000018_0001
20 25 30 35 40 45 50 55 60
Time (min) The dissolution profile indicates that use of alkalizer in formulation I I has resulted in relatively faster/immediate release of acetaminophen than that exhibited by formulation I.

Claims

Claims:
1 . A solid oral pharmaceutical composition comprising acetaminophen, dicyclomine, dextropropoxyphene or salts thereof and one or more alkalizers.
2. The solid oral pharmaceutical composition of claim 1 , wherein the amount of acetaminophen in the composition ranges from about 10% w/w to about 95% w/w, the amount of dicyclomine in the composition ranges from about 0.01 % w/w to about 50% w/w and the amount of dextropropoxyphene in the composition ranges from about 0.5% w/w to about 70% w/w of the composition.
3. The solid oral pharmaceutical composition of claim 1 , wherein alkalizer comprises one or more sodium carbonate, sodium bicarbonate, lithium carbonate, lithium bicarbonate, potassium carbonate, potassium bicarbonate, triethylamine, tributylamine, and N-methylmorpholine, sodium phosphate, potassium phosphate, calcium phosphate, magnesium phosphate, aluminium phosphate, citric acid, potassium citrate, aluminium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, trihydroxymethylaminomethane or mixtures thereof.
4. The solid oral pharmaceutical composition of claim 1 , wherein the alkalizer comprises sodium bicarbonate.
5. The solid oral pharmaceutical composition of claim 1 , wherein the alkalizer is present in amount of about 0.1 % w/w to about 50% w/w of the composition.
6. The solid oral pharmaceutical composition of claim 1 , wherein acetaminophen or its salt is present in the form of at least two different portions of the particles each portion having different particle size.
7. The solid oral pharmaceutical composition of claim 1 , wherein acetaminophen or its salt is present in the form mixture of particles having size less than about 300 microns and particles having size in the range of about 300 microns to about 1200 microns.
8. The solid oral pharmaceutical composition of claim 1 , wherein the composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 90% of the total acetaminophen is released until 20 minutes; and more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 1 dissolution test method at 100 rpm using 900ml of pH 4.5 acetate buffer for 60 minutes.
9. The solid oral pharmaceutical composition of claim 1 , wherein the composition exhibits a dissolution profile such that more than about 60% of the total acetaminophen is released until 10 minutes; more than about 85% of the total acetaminophen is released until 20 minutes; more than about 95% of the total acetaminophen is released until 60 minutes when tested according to USP Apparatus 2 (paddle with sinker) dissolution test method at 30 rpm using 900ml of 0.05M HCI for 60 minutes.
10. The solid oral pharmaceutical composition of claim 1 , wherein the composition is in the form of powder, tablets, capsule, granules filled in capsule, tablet in capsule, multilayer tablet, a bilayer tablet, a trilayer tablet, premixed powder filled in capsule.
1 1 . A process of preparing the solid oral pharmaceutical composition of claim 1 , which process comprises steps of:
(a) sifting acetaminophen, dicyclomine & dextropropoxyphene or salts thereof, one or more alkalizers and one or more pharmaceutically acceptable excipients, and
(b) formulating the mixture prepared in step (a) in a solid oral dosage form.
12. A solid oral pharmaceutical composition of claim 1 , wherein the composition exhibits immediate release of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof.
13. A solid oral pharmaceutical composition comprising -
(a) about 40% w/w to about 80% w/w of acetaminophen or salts thereof;
(b) about 0.1 % w/w to about 20% w/w of dicyclomine or salts thereof;
(c) about 2% w/w to about 40% w/w of dextropropoxyphene or salts thereof; (d) about 1 % w/w to about 30% w/w of alkalizer;
(e) about 1 % w/w to about 60% w/w of filler; and
(f) about 0.001 % w/w to about 10% w/w of lubricant.
PCT/IB2014/062251 2013-06-22 2014-06-16 Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof WO2014203140A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2111/MUM/2013 2013-06-22
IN2110/MUM/2013 2013-06-22
IN2110MU2013 IN2013MU02110A (en) 2013-06-22 2014-06-16
IN2111MU2013 IN2013MU02111A (en) 2013-06-22 2014-06-16

Publications (1)

Publication Number Publication Date
WO2014203140A1 true WO2014203140A1 (en) 2014-12-24

Family

ID=51257540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062251 WO2014203140A1 (en) 2013-06-22 2014-06-16 Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof

Country Status (1)

Country Link
WO (1) WO2014203140A1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO2002100391A1 (en) * 2001-06-08 2002-12-19 Smithkline Beecham P.L.C. Swallow tablet comprising paracetamol
US20050276847A1 (en) * 2004-05-28 2005-12-15 Roberts Michael S Oral delivery system
US7038085B2 (en) 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US7776844B2 (en) 2006-01-10 2010-08-17 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
US8263125B2 (en) 2002-08-05 2012-09-11 Torrent Pharmaceuticals Limited Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952402A (en) 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6730321B2 (en) 1998-04-02 2004-05-04 Impax Pharmaceuticals, Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO2002100391A1 (en) * 2001-06-08 2002-12-19 Smithkline Beecham P.L.C. Swallow tablet comprising paracetamol
US8263125B2 (en) 2002-08-05 2012-09-11 Torrent Pharmaceuticals Limited Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7038085B2 (en) 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20050276847A1 (en) * 2004-05-28 2005-12-15 Roberts Michael S Oral delivery system
US7776844B2 (en) 2006-01-10 2010-08-17 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Matched Brand/Brands of Dicyclomine (Dicycloverine), Acetaminophen, Dextropropoxyphene", MEDGUIDEINDIA.COM, 2010, XP002729463, Retrieved from the Internet <URL:http://www.medguideindia.com/find_brand_bygeneric.php?gen_mask=,10,296,1572,> [retrieved on 20140909] *
"Parvon Spas - Capsule, Jagsonpal Pharmaceuticals Ltd.", DAWA BAZAR IN ACCELERATING THE PHARMA TRADE IN INDIA, 2012, XP002729462, Retrieved from the Internet <URL:http://www.dawabazar.in/parvon_spas/jagsonpal_pharmaceuticals_ltd/14624399> [retrieved on 20140915] *
ROSTAMI-HODJEGAN A ET AL: "A NEW RAPIDLY ABSORBED PARACETAMOL TABLET CONTAINING SODIUM BICARBONATE. II. DISSOLUTION STUDIES AND IN VITRO/IN VIVO CORRELATION", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 28, no. 5, 1 May 2002 (2002-05-01), pages 533 - 543, XP001097705, ISSN: 0363-9045, DOI: 10.1081/DDC-120003449 *
S VENKATA RAGHAVA ET AL: "FATALITY FROM SPASMO-PROXYVON ADDICTION: A FEW CASES", JOURNAL OF THE INDIAN SOCIETY OF TOXICOLOGY, vol. 6, no. 2, July 2010 (2010-07-01) - December 2010 (2010-12-01), pages 47 - 49, XP008171964 *

Similar Documents

Publication Publication Date Title
US20090238873A1 (en) Extended release formulation containing a wax
HU227515B1 (en) Controlled release oxycodone compositions
US20120015031A1 (en) Novel gastro-retentive dosage forms
KR20110117216A (en) Sustained release oral dosage forms of an r-baclofen prodrug
AU2016203567B2 (en) Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
EA026815B1 (en) Oral dosage form comprising palonosetron and netupitant, capsule dosage form, method of treating nausea and vomiting
US20060159752A1 (en) Extended release matrix tablets
EP2867199A2 (en) Stable compositions of fesoterodine
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
KR20160030093A (en) Orally disintegrating tablet
US20060147530A1 (en) Sustained release compositions containing alfuzosin
JP6636532B2 (en) Pregabalin-containing oral sustained release triple tablets
WO2014203140A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
AU2006301573B2 (en) Retard formulation for pralnacasan
WO2011126327A2 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
JP6708853B2 (en) Pregabalin-containing highly swellable sustained-release triple tablet
WO2021005129A1 (en) Combination of ibuprofen and tramadol for relieving pain
CN111643506A (en) Olanzapine fluoxetine compound capsule preparation and preparation method thereof
WO2017111178A1 (en) Solid preparation
MXPA06007779A (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14744957

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14744957

Country of ref document: EP

Kind code of ref document: A1